MENU
Menu
Share 2016-09-29 17:29 RATOS B 40.64 SEK

TFS

  • Daniel Spasic

    CEO

TFS performs clinical trials in the human phase on behalf of pharmaceutical, biotechnology and medical device companies.

In 2015 sales amounted to SEK 689m and EBITA to SEK 45m. Average number of employees 646.

Development 2016

(From Ratos's interim report January-June 2016)

  • Service sales* amounted to EUR 29.8m (25.4), corresponding to growth of +17%. Continued strong order book and positive book-to-bill ratio (order intake/sales)
  • Ongoing investments in the service range, organisation and operational efficiency in order to strengthen competitiveness
  • Additional purchase price of EUR 4m paid

* According to IFRS, TFS and other contract research organisations (CRO) generate two types of revenue: 1) Service sales (actual revenuegenerating sales) and 2) re-invoicing of expenditure (for example, travel expenses, laboratory costs and other overheads) at no or a very low margin. In all material respects, service sales are the most important when it comes to the company’s performance and earnings.

Read more about TFS